Payment overview · 2025
General Payments
$2,434.42
102 reported records · 26 companies
Healthcare provider profile · identity verified
Ranjit B Tamaskar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WILLOUGHBY, OH · NPI 1912956418
Verified facts
What the public records show
CMS Open Payments records show Ranjit B Tamaskar, M.D. received $2,434.42 in general payments during 2025 across 102 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 759 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $309.22 | 12.7% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $300.43 | 12.3% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $279.42 | 11.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.02 | 9.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $215.13 | 8.8% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $184.02 | 7.6% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $112.29 | 4.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.46 | 4.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.59 | 3.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $65.17 | 2.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $64.37 | 2.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $50.66 | 2.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.80 | 2.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.71 | 1.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.37 | 1.8% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.89 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.44 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.01 | 1.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.97 | 1.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.71 | 1.3% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.39 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.36 | 0.9% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.19 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.40 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.90 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,391.92 | 101 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $300.43 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $279.42 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $262.49 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $222.46 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.74 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.34 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.01 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.06 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $112.29 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.96 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $99.46 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.59 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.86 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $65.17 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $65.17 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64.37 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $50.66 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $11.56 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 759 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 172 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 290 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 91 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
172 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
290 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
290 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
759 | 98 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1271 | 304 |
| Gabapentin | Gabapentin | 761 | 168 |
| Eliquis | Apixaban | 759 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 728 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 622 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 542 | 150 |
| Potassium Chloride | Potassium Chloride | 512 | 78 |
| Lisinopril | Lisinopril | 503 | 142 |
| Furosemide | Furosemide | 501 | 125 |
| Trazodone Hcl | Trazodone Hcl | 443 | 69 |
| Metformin Hcl | Metformin Hcl | 431 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 396 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 93 |
| Losartan Potassium | Losartan Potassium | 372 | 97 |
| Sertraline Hcl | Sertraline Hcl | 359 | 53 |
| Carvedilol | Carvedilol | 346 | 64 |
| Famotidine | Famotidine | 341 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 310 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 81 |
| Jardiance | Empagliflozin | 290 | 51 |
| Omeprazole | Omeprazole | 282 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 79 |
| Buspirone Hcl | Buspirone Hcl | 269 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 265 | 53 |
| Baclofen | Baclofen | 255 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 204 | 51 |
| Divalproex Sodium | Divalproex Sodium | 203 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 94 |
| Donepezil Hcl | Donepezil Hcl | 185 | 31 |
| Mirtazapine | Mirtazapine | 179 | 38 |
| Farxiga | Dapagliflozin Propanediol | 172 | 39 |
| Torsemide | Torsemide | 169 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 168 | 31 |
| Memantine Hcl | Memantine Hcl | 160 | 28 |
| Simvastatin | Simvastatin | 151 | 42 |
| Amiodarone Hcl | Amiodarone Hcl | 150 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 148 | 19 |
| Spironolactone | Spironolactone | 142 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 51 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 33 |
| Allopurinol | Allopurinol | 133 | 34 |
| Levetiracetam | Levetiracetam | 130 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 39 |
| Glimepiride | Glimepiride | 128 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 122 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 121 | 71 |
| Azithromycin | Azithromycin | 116 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 57 |
| Ezetimibe | Ezetimibe | 115 | 34 |
| Xarelto | Rivaroxaban | 110 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 107 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 105 | suppressed |
| Cephalexin | Cephalexin | 104 | 62 |
| Januvia | Sitagliptin Phosphate | 104 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 101 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 27 |
| Atenolol | Atenolol | 97 | 19 |
| Bupropion Xl | Bupropion Hcl | 97 | 18 |
| Risperidone | Risperidone | 96 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 28 |
| Alprazolam | Alprazolam | 88 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 84 | 17 |
| Finasteride | Finasteride | 83 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 82 | 16 |
| Nyamyc | Nystatin | 82 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 17 |
| Midodrine Hcl | Midodrine Hcl | 79 | 14 |
| Montelukast Sodium | Montelukast Sodium | 79 | 20 |
| Topiramate | Topiramate | 79 | 18 |
| Nystatin | Nystatin | 78 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 25 |
| Prednisone | Prednisone | 76 | 39 |
| Entresto | Sacubitril/Valsartan | 73 | 15 |
| Glipizide | Glipizide | 71 | 15 |
| Warfarin Sodium | Warfarin Sodium | 71 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 68 | 16 |
| Sucralfate | Sucralfate | 68 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 50 |
| Methylprednisolone | Methylprednisolone | 65 | 54 |
| Meloxicam | Meloxicam | 64 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 17 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 30 |
| Ibuprofen | Ibuprofen | 56 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 36 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 52 | suppressed |
| Ozempic | Semaglutide | 51 | 14 |
| Insulin Lispro | Insulin Lispro | 50 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | suppressed |
| Valsartan | Valsartan | 47 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | suppressed |
| Methocarbamol | Methocarbamol | 45 | 21 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 18 |
| Lovastatin | Lovastatin | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 42 | 18 |
| Enalapril Maleate | Enalapril Maleate | 41 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 40 | 15 |
| Novolog | Insulin Aspart | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Humalog | Insulin Lispro | 39 | 13 |
| Latanoprost | Latanoprost | 39 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 36 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 34 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 23 |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 15 |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 11 |
| Budesonide | Budesonide | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 15 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 15 |
| Cyclosporine | Cyclosporine | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Dexamethasone | Dexamethasone | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | 12 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Xtampza Er | Oxycodone Myristate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nystop | Nystatin | 16 | 12 |
| Ramipril | Ramipril | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Acetylcysteine | Acetylcysteine | 11 | suppressed |
| Alrex | Loteprednol Etabonate | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,434.42 · 102 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, ULTOMIRIS, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error